Anticoagulation in Glaucoma Surgery
Anticoagulation in Glaucoma Surgery
复制标题
DOI：
10.1080/08820538.2017.1353828
复制
发表时间：
2018-01-01
影响因子：
1.7
通讯作者：
Turalba, Angela
中科院分区：
文献类型：
--
作者：
Rahman, Shiraaz I.;Turalba, Angela
通常使用抗凝药物，特别是在老年人群中。有许多系统性疾病和情况需要调节凝血以防止严重的不良后果。虽然在白内障手术中使用它们有一些共识，但在青光眼手术中使用它们的管理却不太确定。在考虑抗凝治疗时，青光眼手术是一个独特的挑战。目前，关于青光眼手术中抗凝治疗的外科医生实践存在很大差异。根据现有证据，目前尚不清楚在有或没有桥接治疗的情况下保持抗凝是否有益，从而导致计划的手术。考虑到与暂停抗凝治疗相关的潜在严重不良结局，应谨慎地改变青光眼手术的这些药物，并与这些药物的主要处方者协商。
Anticoagulation medications are used commonly, particularly in an elderly population. There are many systemic diseases and scenarios that require modulation of coagulation to prevent serious adverse outcomes. While there is some consensus about their use in cataract surgery, there is less certainty about their management with glaucoma surgery. Glaucoma surgery presents a unique challenge when considering anticoagulation. Currently, there is great diversity in surgeon practices regarding anticoagulation in glaucoma surgery. Based on available evidence, it is unclear whether it is beneficial to hold anticoagulation, with or without bridging therapy, leading up to a planned surgery. Considering the potential serious adverse outcomes related to holding anticoagulation therapy, altering these medications for glaucoma surgery should be done sparingly and in consultation with the primary prescriber of such medications.